Patents by Inventor Matthew David Burr Moran

Matthew David Burr Moran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20230052140
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 16, 2023
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • IGF-1R monoclonal antibodies and uses thereof
    Patent number: 11433148
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 6, 2022
    Assignee: Centre for Probe Development and Commercialization
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant, Alla Darwish
  • IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20190083662
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Application
    Filed: May 4, 2018
    Publication date: March 21, 2019
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant
  • IGF-1R monoclonal antibodies and uses thereof
    Patent number: 10093741
    Abstract: The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: October 9, 2018
    Assignee: Fusion Pharmaceuticals Inc.
    Inventors: Eric Steven Burak, John Richard Forbes, Matthew David Burr Moran, Ryan Wayne Simms, John Fitzmaurice Valliant